Risk of venous thromboembolism in Korean patients with rheumatoid arthritis treated with Janus kinase inhibitors: A nationwide population-based study
Main finding · VTE (after sIPTW)Result — go to the resultHazard ratio 0.18 95% CI 0.01–3.47Authors' conclusion
There is no increased risk of VTE in RA patients treated with JAKis compared with TNF inhibitors in Korea.
Study context
- Population
- Patients with prevalent rheumatoid arthritis (RA) starting JAKi or TNFi, National Health Insurance Service database, Korea, 2015–2019; excluded prior venous thromboembolism (VTE) or anticoagulant use within 30 days
- Participants
- 4,178 patients
- Exposure
- JAKi vs TNFi in RA
- JAKin = 871
- Tumour necrosis factor (TNF) inhibitorn = 3,307reference
- Outcome
- VTE
Methodological detailsnationwide population-based, stabilised inverse probability of treatment weighting (sIPTW) using propensity score, Cox proportional hazard model with death as competing risk, Follow-up: 1,029.2 person-years (PYs) (JAKi) and 5,940.3 PYs (TNFi)
- Nationwide population-based
- Stabilised inverse probability of treatment weighting (sIPTW) using propensity score
- Cox proportional hazard model with death as competing risk
- Follow-up: 1,029.2 PYs (JAKi) and 5,940.3 PYs (TNFi)
Main finding
VTE (after sIPTW)
Hazard ratio
0.18
95% CI 0.01–3.47
By group
JAKivs TNFi
HR 0.18 (95% CI 0.01–3.47)
As reported in the abstract
Observational data: associations, not effects.
Original publication
Risk of venous thromboembolism in Korean patients with rheumatoid arthritis treated with Janus kinase inhibitors: A nationwide population-based study. Semin Arthritis Rheum. Published 5 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →